Aehr Test Systems has recovered sharply from its pre-earnings collapse, but the post-print bounce has done little to dislodge a meaningful short position — and the executive suite was selling into the rally the moment results crossed.
The insider activity is the most striking detail of the past two days. Every named senior officer sold shares on July 13, the trading session immediately following the July 8 earnings event: the CEO unloaded 4,404 shares at $72.60, the CFO sold 988, the COO sold 387, and the CTO sold 423. The EVP continued selling on July 14. These are small transactions in dollar terms — the CEO's sale totalled roughly $320,000 — and all carry a significance score of just 1, suggesting they reflect pre-arranged plans rather than discretionary bets against the stock. But the timing and breadth of the cluster, with five C-suite names selling on the same day into a 7.6% weekly gain, is a visible signal worth noting. Net insider activity over the past 90 days remains a modest positive at roughly 50,000 shares, so this is trimming rather than distribution.
Short interest tells a story of patient bears who have not yet blinked. At 14.2% of free float — around 4.25 million shares — the short position has actually edged up roughly 3% over the past week, even as the stock gained more than 7%. That's a meaningful divergence: shorts added exposure into the bounce rather than covering. The borrow market remains very loose, with availability running near 792% — nearly eight times as much stock available to lend as is currently borrowed. Cost to borrow is a negligible 0.45%, slightly higher than last week but still well below any level that would pressure shorts to cover on economics alone. The prior earnings preview noted availability at 974%; that has tightened modestly, but the lending environment remains one that makes it easy and cheap to hold a short position.
Options positioning has shifted toward calls in a way that reinforces the bullish price action. The put/call ratio has dropped to 0.81, almost two standard deviations below its 20-day average of 0.89 — the most call-skewed reading in the past year, with the 52-week low sitting at 0.286 and the high at 1.07. A month ago, the ratio was running above 1.05, reflecting heavy put demand ahead of the earnings collapse. The rotation into calls since then is consistent with investors repositioning for further recovery, though the low PCR can also reflect complacency rather than conviction.
The Street's read on AEHR is stale enough to treat with caution. The most recent analyst actions date from early March — William Blair upgraded to Outperform, while Freedom Broker lifted its Hold target to $38. The consensus mean target sits at $108, but with the stock now at $72 and the most recent individual targets in the $21–$38 range, there is almost certainly a significant gap between the headline average and where active coverage currently sits. The ORTEX short score has eased slightly to 51.7, down from 52.3 earlier in the week, consistent with a stock that is no longer pressing to new short extremes. Factor scores reinforce the mixed picture: EPS momentum over 30 days ranks in the 75th percentile, but 90-day EPS momentum sits at zero, and the short score rank is in just the 15th percentile of the universe, suggesting the short position is not yet extreme by cross-sectional standards.
Peers are broadly rallying alongside AEHR. CAMT gained 12.5% on the week, FORM rose 9.7%, and SMTC added 11.8%, so the sector tailwind is real. What distinguishes AEHR's setup is the combination of a still-elevated short position that grew into this week's strength, a management team that sold into the same rally, and options positioning that has turned notably bullish. Whether the shorts or the call buyers are reading the situation more accurately becomes clearer when AEHR reports again — the next event is pencilled in for October 5.
See the live data behind this article on ORTEX.
Open AEHR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
